Cinacalcet treatment is associated with decreased overall and cardiovascularmortality among younger dialysis patients and those with moderate secondary hyperparathyroidism (SHPT) and who do not have diabetes, researchers reportedonline in the European Journal of International Medicine

Claudia Friedl, MD, of the Medical University of Graz, Graz, Austria, and colleaguesstudied 7983 dialysis patients, of whom 1572 (19.7%) were prescribedcinacalcet. A total of 3574 patients (44.8%) died, 1342 (16.8%) from cardiovascularcauses, during a median follow-up of 2.7 years. Survival analysis in apropensity-score matched study population showed lower all-cause mortality forcinacalcet-treated versus untreated patients in subsets of patients characterized byyounger age, low prevalence of diabetes, intact parathyroid hormone levels of 300to 599 pg/mL, and concomitant therapy with vitaminD and phosphate binders.

Related Articles

Continue Reading